Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Tafenoquine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,132Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sixty Degrees Ensures Tafenoquine Supply With KODATEF Import
    Sixty Degrees Ensures Tafenoquine Supply With KODATEF Import

    11 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/11/3024516/0/en/Sixty-Degrees-Pharmaceuticals-to-Ensure-Continuity-of-Tafenoquine-Supply-in-U-S-by-Importing-Limited-Quantity-of-KODATEF.html

    GLOBENEWSWIRE
    11 Feb 2025
    Share Share
    60 Degrees Pharma IRB Approved For Tafenoquine Babesiosis Study
    60 Degrees Pharma IRB Approved For Tafenoquine Babesiosis Study

    28 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/28/3016354/0/en/60-Degrees-Pharma-Announces-IRB-Approval-of-Phase-II-Study-to-Evaluate-Tafenoquine-for-Chronic-Babesiosis.html

    GLOBENEWSWIRE
    28 Jan 2025
    Share Share
    60 Degrees Enrolls 1st Patient In Tafenoquine Babesiosis Study
    60 Degrees Enrolls 1st Patient In Tafenoquine Babesiosis Study

    08 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/08/3006241/0/en/60-Degrees-Pharmaceuticals-Enrolls-First-Patient-in-Tafenoquine-Expanded-Access-Clinical-Study-for-Persistent-B-microti-Babesiosis.html

    GLOBENEWSWIRE
    08 Jan 2025
    Share Share
    60 Degrees Pharma Expands Tafenoquine Clinical Trial for Babesiosis
    60 Degrees Pharma Expands Tafenoquine Clinical Trial for Babesiosis

    11 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/11/2995432/0/en/60-Degrees-Pharmaceuticals-Expands-Tafenoquine-Clinical-Trial-for-Babesiosis-to-Brigham-and-Women-s-Hospital.html

    GLOBENEWSWIRE
    11 Dec 2024
    Share Share
    60 Degrees Pharma Plans Arakoda® Pilot Before US Launch Expansion
    60 Degrees Pharma Plans Arakoda® Pilot Before US Launch Expansion

    03 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/03/2957754/0/en/60-Degrees-Pharmaceuticals-Inc-Announces-ARAKODA-Promotional-Pilot-in-Advance-of-Expanded-U-S-Launch.html

    GLOBENEWSWIRE
    03 Oct 2024
    Share Share
    60 Degrees Pharma Closes $4M Private Placement At-Market Under Nasdaq
    60 Degrees Pharma Closes $4M Private Placement At-Market Under Nasdaq

    06 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/06/2942158/0/en/60-Degrees-Pharmaceuticals-Inc-Announces-Closing-of-4-Million-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html

    GLOBENEWSWIRE
    06 Sep 2024
    Share Share